about
Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumorsFunction-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF InhibitorCombinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology GroupBeneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanomaIdentification of PLX4032-resistance mechanisms and implications for novel RAF inhibitorsInsight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanomaActivating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells.NF-κB Regulation of c-FLIP Promotes TNFα-Mediated RAF Inhibitor Resistance in MelanomaErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanomaActivation status of the pregnane X receptor influences vemurafenib availability in humanized mouse models.Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanomaCo-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma.Adaptive resistance to RAF inhibitors in melanoma.Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma.The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox.Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations.The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro.BMS-536924, an ATP-competitive IGF-1R/IR inhibitor, decreases viability and migration of temozolomide-resistant glioma cells in vitro and suppresses tumor growth in vivo.Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells.ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cellsSmall molecules against B-RAF (BRAF) Val600Glu (V600E) single mutationERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma.DEK oncogene is overexpressed during melanoma progression.Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance.
P2860
Q28468571-917E1D07-7FF5-43C8-9003-AC0CDEB2825FQ29542169-3BB6300E-9F69-4D5F-919D-1801BFE850D1Q30277902-529FA128-7158-45FC-B7D7-CCEFB4AA96E3Q33587905-0C49EE2E-E4F2-4E16-89AE-8BD090CC6A85Q33610782-C5532297-A842-413F-A06C-85A5AC56BF5FQ33784436-AF2128C3-A09F-4980-A1EA-E1170891F57FQ34669746-A9270242-DDB9-4862-B719-55FC3196DB1FQ35033377-27C46DC7-D923-40EB-9D2B-EBF88C4FAC0AQ35250612-8E7211FC-82CA-4515-A407-3A8FA2042761Q35692123-FE2084DE-0BA5-490A-8C09-A33D5A665761Q35738534-5ECB1B1A-DA57-4CEA-BFB9-2BF3C725E6DCQ36021891-2C4B9678-B89D-43A2-8CE3-04BF51CD9836Q36115818-1BEA5509-414E-4239-9A80-B1FF10EF6D33Q36251418-7864D1AE-3DE3-407D-9C75-3705A92A7A5DQ36291134-F819FBB1-5D9F-48FE-8C85-4939BDA7EE8DQ36821239-75A9BDDE-E4F5-41A7-81B4-D3ED8D31399FQ38211773-DE5E2AEF-8D09-43D2-8619-065553D19FD7Q38238524-F8E43464-1B9B-4ECF-94CC-F21D1AE54C29Q38412577-C74C9C2A-BC37-4CF5-A74A-498D0756AA69Q38773565-3588CD20-73B0-42CA-9F25-21B4F7F45D7FQ38934404-CE5E888D-8C29-47AF-A1D1-CDBB9846E2E0Q38983353-BC324396-4BA9-4323-842B-F8857F755CC2Q39620395-AE66B8D0-0FC6-4C41-A144-ED3402491CF7Q40847850-D610D30C-ABD8-48D7-8EFD-F331F4A39FADQ42211295-E70E6CF9-C48E-457B-A344-91462873753CQ42424413-F7EABFAE-46DC-4AB3-AC7B-BD8FFFC3A1AFQ47203970-F014353A-8863-4825-B9B8-C6FA7AE7AA78Q51300425-64235DC4-90BB-40D2-88CB-17451EC7E88EQ55424318-95A782FA-8325-412B-B644-488213F0620D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Resistance to RAF inhibitors revisited.
@en
Resistance to RAF inhibitors revisited.
@nl
type
label
Resistance to RAF inhibitors revisited.
@en
Resistance to RAF inhibitors revisited.
@nl
prefLabel
Resistance to RAF inhibitors revisited.
@en
Resistance to RAF inhibitors revisited.
@nl
P2860
P921
P356
P1476
Resistance to RAF inhibitors revisited.
@en
P2093
Andrew E Aplin
Yongping Shao
P2860
P2888
P304
P356
10.1038/JID.2013.358
P407
P577
2013-10-10T00:00:00Z
2014-02-01T00:00:00Z
P5875
P6179
1027475449